Connect with us at LinkedInFollow us on Twitter
A diagnostic to give clinicians a quick indication of internal bleeding - developed in collaboration with surgeons.

The purpose of the test is to quickly stratify patients with massive traumatic injuries by who will truly benefit from a blood transfusion, and those who do not require it: using a portable new instrument.

The development path included forming a collaborative interaction with a facilitation infrastructure organisation - National Institute for Health Research (NIHR) that has enabled HBL access to leading clinical researchers, front-line health-care professionals including clinicians and nurses, patient and public involvement and (PPI/E), NICE, and commissioners.  HBL has been able to establish a clear plan to demonstrate the clinical value of the technology and demonstrate the potential for adoption into the NHS and beyond. 

A protocol was developed and ethics approval received.  The pilot trial was completed with 25 blood samples from “code red” patients who are already being tested for coagulopathy laboratory instrument. 

The CoaguScan device is designed to guide clinicians to how which drugs and blood products that the patient will benefit the most from.

Mr. Mansoor Khan, Consultant Military And Trauma Surgeon with the Trust said:

“We are confident this device which has been through the first trial phase known as the proof of concept phase at St Mary’s Hospital recently, will ultimately help us to save more lives in the future. 

“Not only does this allow a clinician to know instantly whether a patient requires a blood transfusion or not, which using current methods takes up to one hour to determine – it also allows clinicians to move away from the one size fits all approach when it comes to blood transfusions for patients with severe bleeding."

After the proof of concept trial, the results demonstrated the portable technology was able to identify patients in the same way as a large and heavy laboratory instrument.

In conclusion to a recent NIHR study “CoaguScan appears to be a “game changer” which could bring more reliable results. The device could be easily adapted to different pathways, extending its potential market

For further details contact: Richard Day 01463 216 454

Highland Biosciences
News Headlines

HBL receives ISO9001:2015 Registration

Highland Biosciences Ltd., is pleased to announce that it has been assessed and approved to ISO 9001:2015.   The design, manufacture and s Full Story...

Highland Biosciences Receives Investment to Reduce Pressures in Acute Healthcare

Pressures in Acute Sector are target for SBRI Healthcare funding £700K investment in innovations that target hospital efficiency C Full Story...

HBL to develop field tests for military engines

The project will deliver a fully working prototype condition monitoring device that will support lubrication condition based maintenance.  Mea Full Story...

Scots firm develops potentially lifesaving technology to detect internal bleeding

Extract from the Daily Herald. 14th November 2016. A Scots firm has developed a potentially lifesaving technology which allows doctors to quick Full Story...

St Mary's Hospital Imperial College Trust Collaboration

Trust helps to develop life-saving technology for trauma patients Imperial College Healthcare NHS Trust is helping to develop new technology to Full Story...

HBL - NHS Collaboration showcased at the NIHR Conference at Lady Margaret Hall, Oxford

HBL - NHS Collaboration showcased at the NIHR Diagnostic Technologies Forum at Lady Margaret Hall, Oxford.  This exciting project that combine Full Story...

Highland Biosciences, Ness House, Greenleonachs, Dingwall, Scotland UK IV7 8JD

Tel: 01463 216466 / 01463 216454 Fax: 01463 898011 Mobile: 07736 806158 Email:

Registered in Scotland number: SC296459 | All works © 2012 Highland Biosciences

design & program by plexus media